Abnormal ocular movements in Parkinson's disease. Evidence for involvement of dopaminergic systems. 1989

O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
Department of Medical and Clinical Pharmacology (INSERM U317), Centre Hospitalier Universitaire Purpan, Toulouse, France.

Quantitated automated electro-oculographic data from 45 parkinsonian patients were compared with those from 30 normal control subjects. Patients were selected with idiopathic Parkinson's disease without other associated neurological disease or dementia; 20 had never received antiparkinsonian drugs and in 25 such treatment had been stopped for at least 2 days. Saccade latency, amplitude and peak velocity, smooth pursuit peak velocity, optokinetic nystagmus (OKN) maximal and mean velocities and vestibulo-ocular reflex (VOR) suppression by vision or imagination were significantly altered in patients, whereas VOR gain in darkness was normal. Alterations of saccade latency and smooth pursuit peak velocity were more severe in the more advanced stages of the disease and saccade latency directed towards the symptomatic side was slightly delayed in hemiparkinsonian patients. Saccade amplitude improved 90 min after a single oral dose of L-DOPA. These results suggest a possible dopaminergic control of some ocular movements.

UI MeSH Term Description Entries
D007980 Levodopa The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system. L-Dopa,3-Hydroxy-L-tyrosine,Dopaflex,Dopar,L-3,4-Dihydroxyphenylalanine,Larodopa,Levopa,3 Hydroxy L tyrosine,L 3,4 Dihydroxyphenylalanine,L Dopa
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010300 Parkinson Disease A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75) Idiopathic Parkinson Disease,Lewy Body Parkinson Disease,Paralysis Agitans,Primary Parkinsonism,Idiopathic Parkinson's Disease,Lewy Body Parkinson's Disease,Parkinson Disease, Idiopathic,Parkinson's Disease,Parkinson's Disease, Idiopathic,Parkinson's Disease, Lewy Body,Parkinsonism, Primary
D012027 Reflex, Vestibulo-Ocular A reflex wherein impulses are conveyed from the cupulas of the SEMICIRCULAR CANALS and from the OTOLITHIC MEMBRANE of the SACCULE AND UTRICLE via the VESTIBULAR NUCLEI of the BRAIN STEM and the median longitudinal fasciculus to the OCULOMOTOR NERVE nuclei. It functions to maintain a stable retinal image during head rotation by generating appropriate compensatory EYE MOVEMENTS. Vestibulo-Ocular Reflex,Reflex, Vestibuloocular,Reflexes, Vestibo-Ocular,Reflexes, Vestibuloocular,Reflex, Vestibulo Ocular,Reflexes, Vestibo Ocular,Vestibo-Ocular Reflexes,Vestibulo Ocular Reflex,Vestibuloocular Reflex,Vestibuloocular Reflexes
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D004585 Electrooculography Recording of the average amplitude of the resting potential arising between the cornea and the retina in light and dark adaptation as the eyes turn a standard distance to the right and the left. The increase in potential with light adaptation is used to evaluate the condition of the retinal pigment epithelium. EOG,Electrooculograms,Electrooculogram
D005133 Eye Movements Voluntary or reflex-controlled movements of the eye. Eye Movement,Movement, Eye,Movements, Eye
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
October 2000, Nihon rinsho. Japanese journal of clinical medicine,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
October 2006, Journal of neurology, neurosurgery, and psychiatry,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
January 1991, Acta oto-laryngologica. Supplementum,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
January 2020, Frontiers in pharmacology,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
January 1979, Transactions of the ophthalmological societies of the United Kingdom,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
April 2019, Journal of neural transmission (Vienna, Austria : 1996),
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
May 1993, Annals of neurology,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
June 1984, Neuroscience letters,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
January 1995, No to shinkei = Brain and nerve,
O Rascol, and M Clanet, and J L Montastruc, and M Simonetta, and M J Soulier-Esteve, and B Doyon, and A Rascol
November 2010, Journal of neurology,
Copied contents to your clipboard!